Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Albumin-bound Docetaxel vs Taxotere in Advanced Solid Tumors
NCT04811118Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- May 2021
- Primary completion
- Oct 2022
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of albumin-bound docetaxel in solid tumor (2 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve. Status: unknown.
02
Drugs
albumin-bound docetaxel
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04811118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04811118.